The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Mechanisms of Cardiac Dysfunction Associated With Tyrosine Kinase Inhibitor Cancer Therapeutics
Open accessAbstract
Treatment of patients with cancer has changed radically over the last several years with the advent of “targeted therapeutics.” Whereas traditional chemotherapy was directed at all rapidly dividing cells, whether cancerous or not, today’s anticancer drugs are increasingly tailored to the specific genetics of each cancer. This targeted approach, predominantly via inhibition of tyrosine kinase activity, has markedly improved the management of cancers including chronic myeloid leukemia (CML), breast cancer, gastrointestinal stromal tumor (GIST), renal cell carcinoma (RCC), and colon carcinoma.1–5 Inhibitors of tyrosine kinases are of 2 classes: monoclonal antibodies (mAbs), typically targeting growth factor receptor tyrosine kinases, and small molecules, referred to as tyrosine kinase inhibitors (TKIs), targeting both receptor and nonreceptor tyrosine kinases. The goal of targeted therapy is to improve antitumor activity with fewer toxic side effects than traditional anticancer therapies; given the initial success of this approach, the number of targeted therapy drugs entering into development in the last 5 years has increased dramatically.6,7 However, several recent studies have revealed unanticipated side effects of targeted therapy, including left ventricular (LV) dysfunction and heart failure, the primary manifestations of cardiotoxicity we will be examining here.5,8,9 Herein, we will examine the potential risk of LV dysfunction of targeted therapy and the molecular mechanisms that underlie that risk. We will review the importance of tyrosine kinase signaling pathways both for oncogenesis and for the survival of normal cardiomyocytes. To understand basic mechanisms of cardiomyopathy of TKIs, it is critical to understand 2 general classes of toxicity. The first is “on-target” toxicity, wherein the tyrosine kinase target regulating cancer cell survival and/or proliferation (and therefore a good target in cancer therapy) also serves an important role in normal cardiomyocyte survival, and thus inhibition leads to myocardial dysfunction. “Off-target” toxicity occurs when a TKI leads to toxicity …
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
Signal integration in the endoplasmic reticulum unfolded protein response
Ron, D., & Walter, P. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2199 · Cited by 6,296
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,775
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802
Angiogenesis in life, disease and medicine
Carmeliet, P. (2005) · Nature · doi:10.1038/nature04478 · Cited by 3,482
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J., Lindquist, D., Chan, S., Romieu, C. G., Pienkowski, T., Jagiello-Gruszfeld, A., Crown, J., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,425
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170
Demetri, G. D., van Oosterom, A. T., Garrett, C. R., Blackstein, M. E., Shah, M. H., Verweij, J., McArthur, G., Judson, I. R., Heinrich, M. C., Morgan, J. A., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69446-4 · Cited by 2,607
Trastuzumab — Mechanism of Action and Use in Clinical Practice
Hudis, C. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmra043186 · Cited by 2,585
Angiogenesis: an organizing principle for drug discovery?
Folkman, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2115 · Cited by 2,246
A Selective Inhibitor of eIF2α Dephosphorylation Protects Cells from ER Stress
Boyce, M., Bryant, K. F., Jousse, C., Long, K., Harding, H. P., Scheuner, D., Kaufman, R. J., Ma, D., Coen, D. M., Ron, D., et al. (2005) · Science · doi:10.1126/science.1101902 · Cited by 1,403
Tyrosine Kinases as Targets for Cancer Therapy
Krause, D. S., & Van Etten, R. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra044389 · Cited by 1,387
Requirement for neuregulin receptor erbB2 in neural and cardiac development
Lee, K.-F., Simon, H., Chen, H., Bates, B., Hung, M.-C., & Hauser, C. (1995) · Nature · doi:10.1038/378394a0 · Cited by 1,290
Multiple essential functions of neuregulin in development
Meyer, D., & Birchmeier, C. (1995) · Nature · doi:10.1038/378386a0 · Cited by 1,262
Folkman, J. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.57.121304.131306 · Cited by 1,209
Faivre, S., Delbaldo, C., Vera, K., Robert, C., Lozahic, S., Lassau, N., Bello, C., Deprimo, S., Brega, N., Massimini, G., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.2194 · Cited by 1,164
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate
Kerkelä, R., Grazette, L., Yacobi, R., Iliescu, C., Patten, R., Beahm, C., Walters, B., Shevtsov, S., Pesant, S., Clubb, F. J., et al. (2006) · Nature Medicine · doi:10.1038/nm1446 · Cited by 1,159
Self-citationCardiotoxicity associated with tyrosine kinase inhibitor sunitinib
Chu, T. F., Rupnick, M. A., Kerkela, R., Dallabrida, S. M., Zurakowski, D., Nguyen, L., Woulfe, K., Pravda, E., Cassiola, F., Desai, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61865-0 · Cited by 1,083
Self-citationQuantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors
Bantscheff, M., Eberhard, D., Abraham, Y., Bastuck, S., Boesche, M., Hobson, S., Mathieson, T., Perrin, J., Raida, M., Rau, C., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1328 · Cited by 1,034
Shiojima, I. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24682 · Cited by 939
p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload
Sano, M., Minamino, T., Toko, H., Miyauchi, H., Orimo, M., Qin, Y., Akazawa, H., Tateno, K., Kayama, Y., Harada, M., et al. (2007) · Nature · doi:10.1038/nature05602 · Cited by 905
ErbB2 is essential in the prevention of dilated cardiomyopathy
Crone, S. A., Zhao, Y.-Y., Fan, L., Gu, Y., Minamisawa, S., Liu, Y., Peterson, K. L., Chen, J., Kahn, R., Condorelli, G., et al. (2002) · Nature Medicine · doi:10.1038/nm0502-459 · Cited by 903
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition
Force, T., Krause, D. S., & Van Etten, R. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2106 · Cited by 801
Self-citationComparing antibody and small-molecule therapies for cancer
Imai, K., & Takaoka, A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1913 · Cited by 792
Molecular basis for sunitinib efficacy and future clinical development
Faivre, S., Demetri, G., Sargent, W., & Raymond, E. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2380 · Cited by 721
Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy
Weinstein, I. B., & Joe, A. K. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0558 · Cited by 705
Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy
Pandit, B., Sarkozy, A., Pennacchio, L. A., Carta, C., Oishi, K., Martinelli, S., Pogna, E. A., Schackwitz, W., Ustaszewska, A., Landstrom, A., et al. (2007) · Nature Genetics · doi:10.1038/ng2073 · Cited by 698
Type II Chemotherapy-Related Cardiac Dysfunction: Time to Recognize a New Entity
Ewer, M. S., & Lippman, S. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.827 · Cited by 646
Smith, B. D., Levis, M., Beran, M., Giles, F., Kantarjian, H., Berg, K., Murphy, K. M., Dauses, T., Allebach, J., & Small, D. (2004) · Blood · doi:10.1182/blood-2003-11-3775 · Cited by 632
Tyrosine kinase – Role and significance in Cancer
Paul, M. K., & Mukhopadhyay, A. K. (2004) · International Journal of Medical Sciences · doi:10.7150/ijms.1.101 · Cited by 624
Fazel, S. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27019 · Cited by 517
Neuregulins Promote Survival and Growth of Cardiac Myocytes
Zhao, Y.-Y., Sawyer, D. R., Baliga, R. R., Opel, D. J., Han, X., Marchionni, M. A., & Kelly, R. A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.17.10261 · Cited by 504
Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition
Verheul, H. M. W., & Pinedo, H. M. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2152 · Cited by 503
Vascular Endothelial Growth Factors
Ylä-Herttuala, S., Rissanen, T. T., Vajanto, I., & Hartikainen, J. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.09.053 · Cited by 480
Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy
Özcelik, C., Erdmann, B., Pilz, B., Wettschureck, N., Britsch, S., Hübner, N., Chien, K. R., Birchmeier, C., & Garratt, A. N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122249299 · Cited by 473
β-Arrestin–mediated β1-adrenergic receptor transactivation of the EGFR confers cardioprotection
Noma, T., Lemaire, A., Naga Prasad, S. V., Barki-Harrington, L., Tilley, D. G., Chen, J., Le Corvoisier, P., Violin, J. D., Wei, H., Lefkowitz, R. J., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31901 · Cited by 418
Trastuzumab-Related Cardiotoxicity: Calling Into Question the Concept of Reversibility
Telli, M. L., Hunt, S. A., Carlson, R. W., & Guardino, A. E. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.0106 · Cited by 385
Engel, F. B., Hsieh, P. C. H., Lee, R. T., & Keating, M. T. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607382103 · Cited by 371
GOLLOB, J., WILHELM, S., CARTER, C., & KELLEY, S. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.04.002 · Cited by 360
Hsieh, P. C. H. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25878 · Cited by 357
Izumiya, Y., Shiojima, I., Sato, K., Sawyer, D. B., Colucci, W. S., & Walsh, K. (2006) · Hypertension · doi:10.1161/01.hyp.0000215207.54689.31 · Cited by 326
Mechanisms of Hypertension Associated With BAY 43-9006
Veronese, M. L., Mosenkis, A., Flaherty, K. T., Gallagher, M., Stevenson, J. P., Townsend, R. R., & O'Dwyer, P. J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.0503 · Cited by 324
Cardiac Toxicity in Breast Cancer Survivors: Review of Potential Cardiac Problems
Bird, B. R. J. H., & Swain, S. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1033 · Cited by 307
Kunisada, K., Negoro, S., Tone, E., Funamoto, M., Osugi, T., Yamada, S., Okabe, M., Kishimoto, T., & Yamauchi-Takihara, K. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.1.315 · Cited by 273
Heart failure associated with sunitinib malate: A multitargeted receptor tyrosine kinase inhibitor
Khakoo, A. Y., Kassiotis, C. M., Tannir, N., Plana, J. C., Halushka, M., Bickford, C., Trent, J., Champion, J. C., Durand, J., & Lenihan, D. J. (2008) · Cancer · doi:10.1002/cncr.23460 · Cited by 252
Congestive heart failure is a rare event in patients receiving imatinib therapy
Atallah, E., Durand, J.-B., Kantarjian, H., & Cortes, J. (2007) · Blood · doi:10.1182/blood-2007-01-070144 · Cited by 252
Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes
Grazette, L. P., Boecker, W., Matsui, T., Semigran, M., Force, T. L., Hajjar, R. J., & Rosenzweig, A. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.08.066 · Cited by 241
Self-citationSeries Introduction: JAK-STAT signaling in human disease
Schindler, C. W. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15644 · Cited by 218
Cardiac-specific disruption of the c-raf-1 gene induces cardiac dysfunction and apoptosis
Yamaguchi, O., Watanabe, T., Nishida, K., Kashiwase, K., Higuchi, Y., Takeda, T., Hikoso, S., Hirotani, S., Asahi, M., Taniike, M., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420317 · Cited by 204
Series Introduction: JAK-STAT signaling in human disease
Schindler, C. W. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215644 · Cited by 198
Harris, I. S., Zhang, S., Treskov, I., Kovacs, A., Weinheimer, C., & Muslin, A. J. (2004) · Circulation · doi:10.1161/01.cir.0000138190.50127.6a · Cited by 177
Role of the JAK–STAT pathway in myocardial injury
Barry, S. P., Townsend, P. A., Latchman, D. S., & Stephanou, A. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.12.002 · Cited by 165
An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic
Fernández, A., Sanguino, A., Peng, Z., Ozturk, E., Chen, J., Crespo, A., Wulf, S., Shavrin, A., Qin, C., Ma, J., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32373 · Cited by 158
Kuramochi, Y., Guo, X., & Sawyer, D. B. (2006) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2006.04.007 · Cited by 150
A General Strategy for Creating “Inactive-Conformation” Abl Inhibitors
Barun, O., Nagle, A. S., Adrián, F., Lee, C. R., Ren, P., Wang, X., Sim, T., Xie, Y., Wang, X., Xia, G., et al. (2006) · Chemistry & Biology · doi:10.1016/j.chembiol.2006.05.015 · Cited by 147
Hsieh, P. C. H., MacGillivray, C., Gannon, J., Cruz, F. U., & Lee, R. T. (2006) · Circulation · doi:10.1161/circulationaha.106.639831 · Cited by 146
Platelet-Derived Growth Factor-AB Limits the Extent of Myocardial Infarction in a Rat Model
Edelberg, J. M., Lee, S., Kaur, M., Tang, L., Feirt, N. M., McCabe, S., Bramwell, O., Wong, S. C., & Hong, M. K. (2002) · Circulation · doi:10.1161/hc0502.103672 · Cited by 146
Cardiotoxicity Induced by Chemotherapy and Antibody Therapy
Yeh, E. T. H. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.57.121304.131240 · Cited by 139
Bilancia, D., Rosati, G., Dinota, A., Germano, D., Romano, R., & Manzione, L. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm220 · Cited by 131
Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sezary syndrome
Lenihan, D. J., Alencar, A. J., Yang, D. J., Kurzrock, R., Keating, M. J., & Duvic, M. A. (2004) · Blood · doi:10.1182/blood-2003-07-2345 · Cited by 122
Applying the discovery of the Philadelphia chromosome
Sherbenou, D. W., & Druker, B. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31988 · Cited by 120
Spector, N. L., Yarden, Y., Smith, B. L., Lyass, L., Trusk, P. B., Pry, K. J., Hill, J. E., Xia, W., Seger, R., & Bacus, S. S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701286104 · Cited by 117
Ayach, B., Yoshimitsu, M., Dawood, F., Sun, M., Arab, S., Chen, M., Higuchi, K., Siatskas, C., Lee, P. C., Lim, H., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510997103 · Cited by 115
Self-citationSignaling Through RAS-RAF-MEK-ERK: from Basics to Bedside
Zebisch, A., Czernilofsky, A. P., Kéri, G., Smigelskaite, J., Sill, H., & Troppmair, J. (2007) · Current Medicinal Chemistry · doi:10.2174/092986707780059670 · Cited by 112
Mitogen regulation of c-Raf-1 protein kinase activity toward mitogen-activated protein kinase-kinase
Kyriakis, J. M., Force, T. L., Rapp, U. R., Bonventre, J. V., & Avruch, J. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)82351-1 · Cited by 108
Self-citationCardiotoxicity of Trastuzumab in Clinical Practice
McArthur, H. L., & Chia, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmc070065 · Cited by 85
Stem Cell Factor Deficiency Is Vasculoprotective
Wang, C., Anderson, N. M., Li, S., Szmitko, P. E., Cherng, W., Fedak, P. W. M., Fazel, S. S., Li, R., Yau, T. M., Weisel, R. D., et al. (2006) · Circulation Research · doi:10.1161/01.res.0000243210.79654.fd · Cited by 77
STAT3-Mediated Activation of Myocardial Capillary Growth
Hilfiker‐Kleiner, D., Limbourg, A., & Drexler, H. (2005) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2005.05.002 · Cited by 65
BNP as a marker of the heart failure in the treatment of imatinib mesylate
Park, Y. H., Park, H. J., Kim, B. S., Ha, E., Jung, K. H., Yoon, S. H., Yim, S. V., & Chung, J. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.11.014 · Cited by 59
The Role of Cytoprotective Cytokines in Cardiac Ischemia/Reperfusion Injury
Anderson, C. D., Heydarkhan‐Hagvall, S., Schenke‐Layland, K., Yang, J. Q., Jordan, M. C., Kim, J. K., Brown, D. A., Zuk, P. A., Laks, H., Roos, K. P., et al. (2007) · Journal of Surgical Research · doi:10.1016/j.jss.2007.08.005 · Cited by 19
Cited by
Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw211 · Cited by 2,544
Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.654 · Cited by 1,795
Cardiovascular Complications of Cancer Therapy
Yeh, E. T. H., & Bickford, C. L. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.02.050 · Cited by 1,275
The safety and side effects of monoclonal antibodies
Hansel, T. T., Kropshofer, H., Singer, T., Mitchell, J. A., & George, A. J. T. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3003 · Cited by 1,144
Page, R. L., O’Bryant, C. L., Cheng, D., Dow, T. J., Ky, B., Stein, C. M., Spencer, A. P., Trupp, R. J., & Lindenfeld, J. (2016) · Circulation · doi:10.1161/cir.0000000000000426 · Cited by 471
Metadata
- Authors
- Chen, M. H., Kerkelä, R., & Force, T.
- Venue
- Circulation
- Published
- 2008-07
- Volume
- 118
- Issue
- 1
- Pages
- 84-95
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2157394282
- Cited by
- 379
- References
- 73
- FWCI
- 12.54
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.